Poster Display Therapy

A SYSTEMATIC LITERATURE REVIEW ON THE DISEASE BURDEN OF SECONDARY IMMUNODEFICIENCY DISEASE (SID)

Lecture Time
10:02 - 10:03
Presenter
  • Silvia Sanchez-Ramon, Spain
Room
Poster Area
Date
19.09.2019, Thursday
Session Time
10:00 - 17:00
Board Number
174
Presentation Topic
Therapy

Abstract

Background and Aims

Secondary immunodeficiency disease (SID) is a broad group of diseases characterized by hypogammaglobulinemia and caused by heterogenous etiologies such as hematological malignancies (HMs) and stem cell transplantation (SCT). This study summarized the scientific literature on disease burden of SID in patients with HMs or SCT.

Methods

Systematic searches were conducted through Medline, EMBASE, the Cochrane Library, and other databases to identify English-language articles from 1994 to 2018 reporting on the clinical, humanistic, and economic burden of SID due to HMs or SCT.

Results

Of 906 unique publications, 21 (RCTs, n=6; observational studies, n=15) met eligibility criteria. In most (n=13) studies, patients received intravenous immunoglobulin replacement therapy (IGRT). Several studies indicated significant reductions in the number of serious bacterial infections (n=2), hospitalizations (n=2), and hospital lengths of stay (n=1) with IGRT. Two studies reported reduced usage of antibiotic therapy with IGRT; however, 1 study found no statistically significant difference. Only 3 studies reported on quality of life (all used SF-36 or a derivative measure). No economic studies were identified. Overall, the findings suggested some beneficial effects of IGRT on clinical outcomes and quality of life; however, disparate definitions of SID and serum IgG thresholds, infrequent reporting of statistical significance, and scarcity of clinical trial data post-1990s present potential areas for further investigation.

Conclusions

The paucity of available data indicates a clear unmet need for healthcare professionals to have current evidence available for assessing the efficacy and potential humanistic and economic benefits of IGRT in patients with SID.

Hide